Advisory Insights - Analysis of Upcoming FDA Advisory Committee Meetings

Intra-Cellular Therapies Sinks After FDA Cancels Drug Panel

Bloomberg cites Advisory Insights report highlighting concerns about Lumateperone NDA (accessible via Bloomberg at this link)

Media

Intra-Cellular Therapies Sinks After FDA Cancels Drug Panel Future Article #2